EpiVax, Novozymes fuse drug, delivery protein with $3B market at hand

EpiVax and Novozymes have joined forces, attaching an autoimmune drug to a delivery protein--and by doing so the companies hope to carve themselves a $3 billion piece out of the global autoimmune market. EpiVax's drugs, Tregitopes, are capable of "switching off the immune system" to combat diseases like Type 1 diabetes and multiple sclerosis, according to a report in inPharmatechnologist.com. By combining them with Novozymes' egg-protein-based delivery vehicle, the companies hope to extend the effective range of the drugs by up to 20 days. The delivery platform increases the half-life of EpiVax's treatment with a link to a gene in Novozymes' albumin protein, an effort that is currently in preclinical testing. Story

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

A self-injection pen prefilled with Brussels-based UCB’s Cimzia (certolizumab pegol) has been made available this week in the U.K. after a positive opinion…

Everstone, a private equity firm specializing in India and Southeast Asia, has finally decided to shell out Rs 220 crore ($33 million) to obtain a 70% stake--a…